Cardiol Therapeutics (CRDL) Free Cash Flow: 2021-2022
Historic Free Cash Flow for Cardiol Therapeutics (CRDL) over the last 2 years, with Sep 2022 value amounting to -$1.3 million.
- Cardiol Therapeutics' Free Cash Flow rose 74.40% to -$1.3 million in Q3 2022 from the same period last year, while for Sep 2022 it was -$14.7 million, marking a year-over-year change of. This contributed to the annual value of -$18.3 million for FY2024, which is 2.09% up from last year.
- Per Cardiol Therapeutics' latest filing, its Free Cash Flow stood at -$1.3 million for Q3 2022, which was up 35.50% from -$2.0 million recorded in Q2 2022.
- In the past 5 years, Cardiol Therapeutics' Free Cash Flow ranged from a high of -$1.3 million in Q3 2022 and a low of -$8.2 million during Q1 2022.
- For the 2-year period, Cardiol Therapeutics' Free Cash Flow averaged around -$4.3 million, with its median value being -$4.9 million (2021).
- Examining YoY changes over the last 5 years, Cardiol Therapeutics' Free Cash Flow showed a top increase of 74.40% in 2022 and a maximum decrease of 46.90% in 2022.
- Quarterly analysis of 2 years shows Cardiol Therapeutics' Free Cash Flow stood at -$3.2 million in 2021, then surged by 74.40% to -$1.3 million in 2022.
- Its last three reported values are -$1.3 million in Q3 2022, -$2.0 million for Q2 2022, and -$8.2 million during Q1 2022.